mu-Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome.
Endogenous opioid peptides mainly produced by neurons are also released by immune cells. They bind to mu- (mu-opioid receptor, MOR), delta-, and kappa-opioid receptors. On the basis of studies on mice showing that MOR is the main mediator of the deleterious effects of opioids on immunity, we wondered whether MOR, absent under normal conditions, is expressed in some pathological situations such as lymphomas. mRNA expression for all three opioid receptors was examined in lymph node biopsy samples from patients with non-Hodgkin's B-cell and T-cell lymphomas. We found that MOR and one of its ligands (enkephalin) are simultaneously expressed almost exclusively in lymph nodes from patients with Sézary cutaneous T cell lymphoma. As MOR was undetectable in circulating malignant T lymphocytes and in normal immune cells, we hypothesized that tumor-released cytokines might induce MOR expression in non-neoplastic lymph node cells. The correlation between mRNA levels of MOR and interleukin-13 (IL-13) within lymph nodes from Sézary patients led us to investigate the ability of IL-13 to upregulate MOR expression in normal immune cell subsets. We found that IL-13 upregulates MOR in activated Langerhans cells. Thus, our data suggest that, under pathological conditions, IL-13 overexpression might allow immune-derived endogenous opioids to down-modulate immune response.
Bénard
Alan
A
INSERM U563, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France.
Cavaillès
Pierre
P
Boué
Jérôme
J
Chapey
Emmanuelle
E
Bayry
Jagadeesh
J
Blanpied
Catherine
C
Meyer
Nicolas
N
Lamant
Laurence
L
Kaveri
Srini V
SV
Brousset
Pierre
P
Dietrich
Gilles
G
D001706:Biopsy; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology / Q000502:physiology; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology / Q000502:physiology; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000473:pathology / Q000502:physiology; D015870:Gene Expression / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000502:physiology; D018793:Interleukin-13 / Q000235:genetics* / Q000276:immunology; D007801:Langerhans Cells / Q000473:pathology / Q000502:physiology; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology; D009000:Monocytes / Q000473:pathology / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000235:genetics* / Q000276:immunology; D012751:Sezary Syndrome / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology*; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology*
D018793:Interleukin-13; D012333:RNA, Messenger; D017450:Receptors, Opioid, mu